Cogent Biosciences (COGT) 10-Q2020 Q3 Quarterly report

Filed: 9 Nov 20, 5:13pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: AB, accomplished, ACTIA, advocacy, alter, Andrew, API, appointed, Appointment, ARIAD, Arog, assumed, asterisk, AstraZeneca, AU, Automation, Bayer, BCF, BPMC, carryback, caution, Celldex, Chia, clearance, cloud, CMO, cogent, COGT, companion, complementary, confer, conspiracy, constantly, consummate, Cooperation, CUSIP, cybersecurity, DE, dealing, Deciphera, diagnostic, difficulty, digit, dissemination, dissolution, distinguished, Dr, EMA, EP, escrow, EU, exacerbate, exaggerate, format, formulary, FR, gave, GB, goodwill, Guarantor, guilty, hand, HengRui, highlight, hosting, Immunicum, imprisonment, inconvenient, input, inside, intangible, Internet, inventory, irrespective, IRS, issuable, Jiangsu, JP, Kang, knowledge, left, licensure, lodge, lowest, MAA, mission, misuse, multiplying, mutation, NDA, newly, Ningbo, nonrenewal, nurse, NV, objective, oncogenic, operationally, pace, pediatric, perspective, Pfizer, Physical, physiological, placebo, plc, postpone, practitioner, procurement, promulgated, pronouncement, qui, ratably, redemption, redundant, reevaluate, remeasure, Resignation, resigned, rest, resuming, retroactive, routine, safest, scenario, server, SG, SM, sotio, statutory, stromal, subordinate, substance, substantive, supervisory, symbol, Tai, Taiho, Takeda, tam, temporarily, territory, terrorist, Tianqing, ticker, tied, transmit, undesignated, unwilling, validly, verification, vitro, week, weigh, whistleblower, wind, winding, withdrew, Xencor, ZA, Zai

Removed: antitumor, attack, Bank, bear, borrowed, building, collateralized, curative, depository, function, functionality, immaterial, immune, listed, loan, maturity, microenvironment, overcome, Pacific, prime, PWB, repayment, susceptible, transgene, unallocated, underwriting, West, Western

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

COGT similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Cogent Biosciences, Inc. (the “Company”) for the period ended September 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, John Green, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: November 9, 2020	By:	/s/ John Green
		John Green
		Chief Financial Officer (Principal Financial Officer)